The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Dendritic Cell Reprogramming by Endogenously Produced Lactic Acid
Abstract
The demand for controlling T cell responses via dendritic cell (DC) vaccines initiated a quest for reliable and feasible DC modulatory strategies that would facilitate cytotoxicity against tumors or tolerance in autoimmunity. We studied endogenous mechanisms in developing monocyte-derived DCs (MoDCs) that can induce inflammatory or suppressor programs during differentiation, and we identified a powerful autocrine pathway that, in a cell concentration–dependent manner, strongly interferes with inflammatory DC differentiation. MoDCs developing at low cell culture density have superior ability to produce inflammatory cytokines, to induce Th1 polarization, and to migrate toward the lymphoid tissue chemokine CCL19. On the contrary, MoDCs originated from dense cultures produce IL-10 but no inflammatory cytokines upon activation. DCs from high-density cultures maintained more differentiation plasticity and can develop to osteoclasts. The cell concentration–dependent pathway was independent of peroxisome proliferator–activated receptor γ (PPARγ), a known endogenous regulator of MoDC differentiation. Instead, it acted through lactic acid, which accumulated in dense cultures and induced an early and long-lasting reprogramming of MoDC differentiation. Our results suggest that the lactic acid–mediated inhibitory pathway could be efficiently manipulated in developing MoDCs to influence the immunogenicity of DC vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., & Sallusto, F. (2007) · Nature Immunology · doi:10.1038/ni1496 · Cited by 1,857
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression
Gottfried, E., Kunz-Schughart, L. A., Ebner, S., Mueller-Klieser, W., Hoves, S., Andreesen, R., Mackensen, A., & Kreutz, M. (2006) · Blood · doi:10.1182/blood-2005-05-1795 · Cited by 729
Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells
Everts, B., Amiel, E., van der Windt, G. J. W., Freitas, T. C., Chott, R., Yarasheski, K. E., Pearce, E. L., & Pearce, E. J. (2012) · Blood · doi:10.1182/blood-2012-03-419747 · Cited by 532
Cited by
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Immunometabolism governs dendritic cell and macrophage function
O’Neill, L. A. J., & Pearce, E. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151570 · Cited by 1,694
The Acidic Tumor Microenvironment as a Driver of Cancer
Boedtkjer, E., & Pedersen, S. F. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021119-034627 · Cited by 1,223
Biology and therapeutic potential of interleukin-10
Saraiva, M., Vieira, P., & O’Garra, A. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190418 · Cited by 1,118
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,030
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
“The lack of response of the lymphocytes could also be due to the fact that it has been shown that lactate affects the dendritic cells, prevents their differentiation and makes them tolerogenic, leading to an increase in the production of IL-10, a potent immuno-suppressive cytokine (150).”
BackgroundRegulation of innate immune cell function by mTOR
Weichhart, T., Hengstschläger, M., & Linke, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3901 · Cited by 830
Glycolysis – a key player in the inflammatory response
Soto‐Heredero, G., Gómez de las Heras, M. M., Gabandé‐Rodríguez, E., Oller, J., & Mittelbrunn, M. (2020) · The FEBS Journal · doi:10.1111/febs.15327 · Cited by 641
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Huber, V., Camisaschi, C., Berzi, A., Ferro, S., Lugini, L., Triulzi, T., Tuccitto, A., Tagliabue, E., Castelli, C., & Rivoltini, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.001 · Cited by 595
Lactate in the tumour microenvironment: From immune modulation to therapy
Wang, Z.-H., Peng, W.-B., Zhang, P., Yang, X.-P., & Zhou, Q. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103627 · Cited by 528
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
Lactate: A Metabolic Driver in the Tumour Landscape
Ippolito, L., Morandi, A., Giannoni, E., & Chiarugi, P. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.10.011 · Cited by 523
Romero-Garcia, S., Moreno-Altamirano, M. M. B., Prado-Garcia, H., & Sánchez-García, F. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00052 · Cited by 506
Brown, T. P., & Ganapathy, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107451 · Cited by 481
Tumor glycolysis, an essential sweet tooth of tumor cells
Paul, S., Ghosh, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.007 · Cited by 449
Monocarboxylate transporters in the brain and in cancer
Pérez-Escuredo, J., Van Hée, V. F., Sboarina, M., Falces, J., Payen, V. L., Pellerin, L., & Sonveaux, P. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.03.013 · Cited by 402
Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment
Pérez-Tomás, R., & Pérez-Guillén, I. (2020) · Cancers · doi:10.3390/cancers12113244 · Cited by 385
Lactate-Lactylation Hands between Metabolic Reprogramming and Immunosuppression
Chen, L., Huang, L., Gu, Y., Cang, W., Sun, P., & Xiang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911943 · Cited by 344
Lactic Acid: No Longer an Inert and End-Product of Glycolysis
Sun, S., Li, H., Chen, J., & Qian, Q. (2017) · Physiology · doi:10.1152/physiol.00016.2017 · Cited by 314
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Unravelling the Interplay between Extracellular Acidosis and Immune Cells
Erra Díaz, F., Dantas, E., & Geffner, J. (2018) · Mediators of Inflammation · doi:10.1155/2018/1218297 · Cited by 269
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, A., Cueto, F. J., Garasa, S., Pérez-Gracia, J. L., Sánchez-Arráez, A., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx237 · Cited by 267
Cancer-associated adipocytes as immunomodulators in cancer
Wu, Q., Li, B., Li, J., Sun, S., Yuan, J., & Sun, S. (2021) · Biomarker Research · doi:10.1186/s40364-020-00257-6 · Cited by 105
Metadata
- Authors
- Nasi, A., Fekete, T., Krishnamurthy, A., Snowden, S., Rajnavölgyi, E., Catrina, A. I., Wheelock, C. E., Vivar, N., & Rethi, B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-09
- Volume
- 191
- Issue
- 6
- Pages
- 3090-3099
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1777350112
- Cited by
- 189
- References
- 3
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.